Ecker BL, Vollmer Jr CM, Behrman SW, et al. - Via a cohort study done at 12 institutions from April 1, 2000 to July 31, 2017 that evaluated 357 patients with resected, nonmetastatic ampullary adenocarcinoma having surgery alone or adjuvant therapy (AT), researchers ascertained whether long-term survival following curative-intent resection of ampullary adenocarcinoma may be enhanced by selecting of patients for AT by histologic subtype. In comparison with those with pancreatobiliary subtype, patients with intestinal subtype had a longer median overall survival. Histologic subtype was not related to AT administration. Patients with pancreatobiliary histologic subtype most generally received gemcitabine-based regimens, whereas treatment of those with intestinal histologic subtype was more diverse. AT was not related to a survival advantage for either histologic subtype In the propensity score-matched cohort. Thus, in patients with poor prognostic factors, AT was more commonly used, however, it was not correlated with obvious improvements in survival, despite tumor histologic subtype. Moreover, the value of a multimodality regimen persists to be poorly defined.